Well Bioprints provides B2B drug screening products and services based on advanced 3D cell models generated using our proprietary microfluidic technology. We offer high-throughput combinatorial toxicity screens which provide tens of combinations of different tissue models at hundreds of repetitions in a single screen. Our technology warrants high accuracy of results and reduces your reagent consum...Well Bioprints provides B2B drug screening products and services based on advanced 3D cell models generated using our proprietary microfluidic technology. We offer high-throughput combinatorial toxicity screens which provide tens of combinations of different tissue models at hundreds of repetitions in a single screen. Our technology warrants high accuracy of results and reduces your reagent consumption by even orders of magnitude, while also limiting manual labor and eliminating tittering errors. Well Bioprints will bring the efficiency of your preclinical drug development to a new level.